Oncology News | pharmaphorum

News

TIGIT underwhelms again as Novartis ducks out

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered

News

Gene sequencing for lung cancer under-used in Europe

There is plenty of evidence that next-generation sequencing (NGS) for lung cancer can improve patient outcomes and save healthcare systems money, but access across Europe

News

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

Johnson & Johnson has bolstered its oncology pipeline by licensing a drug from Nanobiotix designed to enhance the effectiveness of radiotherapy for solid tumours.

News

FDA grants Priority Review of Astellas’ zolbetuximab BLA

Astellas Pharma Inc has announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review of its zolbetuximab Biologics License Application

News

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer –

News

AbbVie, Genmab eye label expansion for Epkinly

Just a month after AbbVie and Genmab got FDA approval for Epkinly in one form of non-Hodgkin’s lymphoma, the partners are now preparing to file for a second.

TIGIT underwhelms again as Novartis ducks out

Gene sequencing for lung cancer under-used in Europe

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

FDA grants Priority Review of Astellas’ zolbetuximab BLA

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

AbbVie, Genmab eye label expansion for Epkinly

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks